Literature DB >> 21969553

Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia.

Gregory C Carlson1, Konrad Talbot, Tobias B Halene, Michael J Gandal, Hala A Kazi, Laura Schlosser, Quan H Phung, Raquel E Gur, Steven E Arnold, Steven J Siegel.   

Abstract

DTNBP1 (dystrobrevin binding protein 1) is a leading candidate susceptibility gene in schizophrenia and is associated with working memory capacity in normal subjects. In schizophrenia, the encoded protein dystrobrevin-binding protein 1 (dysbindin-1) is often reduced in excitatory cortical limbic synapses. We found that reduced dysbindin-1 in mice yielded deficits in auditory-evoked response adaptation, prepulse inhibition of startle, and evoked γ-activity, similar to patterns in schizophrenia. In contrast to the role of dysbindin-1 in glutamatergic transmission, γ-band abnormalities in schizophrenia are most often attributed to disrupted inhibition and reductions in parvalbumin-positive interneuron (PV cell) activity. To determine the mechanism underlying electrophysiological deficits related to reduced dysbindin-1 and the potential role of PV cells, we examined PV cell immunoreactivity and measured changes in net circuit activity using voltage-sensitive dye imaging. The dominant circuit impact of reduced dysbindin-1 was impaired inhibition, and PV cell immunoreactivity was reduced. Thus, this model provides a link between a validated candidate gene and an auditory endophenotypes. Furthermore, these data implicate reduced fast-phasic inhibition as a common underlying mechanism of schizophrenia-associated intermediate phenotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969553      PMCID: PMC3203764          DOI: 10.1073/pnas.1109625108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  82 in total

1.  A highly significant association between a COMT haplotype and schizophrenia.

Authors:  Sagiv Shifman; Michal Bronstein; Meira Sternfeld; Anne Pisanté-Shalom; Efrat Lev-Lehman; Avraham Weizman; Ilya Reznik; Baruch Spivak; Nimrod Grisaru; Leon Karp; Richard Schiffer; Moshe Kotler; Rael D Strous; Marnina Swartz-Vanetik; Haim Y Knobler; Eilat Shinar; Jacques S Beckmann; Benjamin Yakir; Neil Risch; Naomi B Zak; Ariel Darvasi
Journal:  Am J Hum Genet       Date:  2002-10-25       Impact factor: 11.025

Review 2.  The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research.

Authors:  Konrad Talbot
Journal:  Prog Brain Res       Date:  2009-11-20       Impact factor: 2.453

3.  N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike features.

Authors:  J M Ford; D H Mathalon; S Kalba; L Marsh; A Pfefferbaum
Journal:  Biol Psychiatry       Date:  2001-05-15       Impact factor: 13.382

4.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

Review 5.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

6.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness.

Authors:  Mark O Cunningham; Jillian Hunt; Steven Middleton; Fiona E N LeBeau; Martin J Gillies; Martin G Gillies; Ceri H Davies; Peter R Maycox; Miles A Whittington; Claudia Racca
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

8.  The functional consequences of cortical circuit abnormalities on gamma oscillations in schizophrenia: insights from computational modeling.

Authors:  Kevin M Spencer
Journal:  Front Hum Neurosci       Date:  2009-10-20       Impact factor: 3.169

9.  Instantaneous modulation of gamma oscillation frequency by balancing excitation with inhibition.

Authors:  Bassam V Atallah; Massimo Scanziani
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

10.  Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice.

Authors:  James David Jentsch; Heather Trantham-Davidson; Corey Jairl; Matthew Tinsley; Tyrone D Cannon; Antonieta Lavin
Journal:  Neuropsychopharmacology       Date:  2009-07-29       Impact factor: 7.853

View more
  61 in total

1.  Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?

Authors:  M J Gandal; R L Anderson; E N Billingslea; G C Carlson; T P L Roberts; S J Siegel
Journal:  Genes Brain Behav       Date:  2012-08       Impact factor: 3.449

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

3.  Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.

Authors:  Yong Chen; Sookhee Bang; Mary F McMullen; Hala Kazi; Konrad Talbot; Mei-Xuan Ho; Greg Carlson; Steven E Arnold; Wei-Yi Ong; Sangwon F Kim
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

Review 4.  Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Authors:  Kim Q Do; Michel Cuenod; Takao K Hensch
Journal:  Schizophr Bull       Date:  2015-06-01       Impact factor: 9.306

5.  Gene dosage in the dysbindin schizophrenia susceptibility network differentially affect synaptic function and plasticity.

Authors:  Ariana P Mullin; Madhumala K Sadanandappa; Wenpei Ma; Dion K Dickman; Krishnaswamy VijayRaghavan; Mani Ramaswami; Subhabrata Sanyal; Victor Faundez
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

Review 6.  Dynamical changes in neurological diseases and anesthesia.

Authors:  Michelle M McCarthy; ShiNung Ching; Miles A Whittington; Nancy Kopell
Journal:  Curr Opin Neurobiol       Date:  2012-03-23       Impact factor: 6.627

Review 7.  Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Authors:  Bernat Kocsis; Ritchie E Brown; Robert W McCarley; Mihaly Hajos
Journal:  CNS Neurosci Ther       Date:  2013-04-24       Impact factor: 5.243

8.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

Review 9.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

Review 10.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.